Possibilities of pharmacokinetic modeling on the example of Diabeton MR (Diamicron MR): point of view of an endocrinologist and pharmacologist

• Alexander S. Ametov
• (Alexander S. Dukhanin
• Olga P. P'yanykh
• Ekaterina E. Erina

Abstract

The differences between the individual sulfonylurea medicines (SUs) are determined by pharmacokinetic properties such as absorption rate and completeness, elimination half-life, and the participation of hepatic and renal elimination mechanisms from the body. The pharmacodynamic features of individual SUs representatives include the nature of their interaction (reversibility, selectivity) with ATP-dependent potassium channels of pancreatic beta cells, the presence and spectrum of pleiotropic effects. A set of distinctive pharmacological features of the drug allows you to implement a personalized approach in choosing SUs. The presented data on the patterns and features of the roadmap Diabeton MR 60 mg indicate important differentiating properties of the drug, including a modified release matrix system; divisible tablet; reversible, highly selective pancreatic sulfonylurea (SUR 1) receptor binding; pronounced antioxidant effect by the scavenger effect mechanism.

Keywords: sulfonylurea preparations, gliclazide, selectivity, rational pharmacotherapy, diabetes mellitus type 2

REFERENCES

1. Lipska K.J., et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017; 40:468–75.

2. «Federal register of diabetes mellitus» of the Russian Federation implemented by the Federal state budgetary institution NMIC of Endocrinology together with JSC «Aston Consulting». URL: http://www.diaregistry.ru/ (date of access October 06, 2020) (in Russian)

3. Ametov A.S. Type 2 diabetes. Problems and solution. Moscow: GEOTAR-Media, 2014: 1032 р. (in Russian)

4. Mkrtumyan A.M., Dukhanin A.S. «Road map» of the drug Diabeton MR. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15(12): 28–38. (in Russian)

5. Singh A.K., Singh R. Is gliclazide a sulfonylurea with difference? Areview in 2016. Expert Rev Clin Pharmacol. 2016; 9 (6): 839–851. DOI: https://doi.org/10.1586/17512433.2016.1159512

6. Song D.K., Ashcroft F.M. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001; 133 (1):193–9. DOI: https://doi.org/10.1038/sj.bjp.0704062

7. Kim S.J., Zhang H., Khaliulin I., et al. Activation of glibenclamide sensitive ATP-sensitive K+ channels during β-adrenergic ally induced metabolic stress produces a substrate for atrial tachyarrhythmia. Circ ArrhythmElectrophysiol. 2012; 5: 1184–92. DOI: https://doi.org/10.1161/CIRCEP.112.975425

8. Abdelmoneim A.S., Hasenbank S.E., Seubert J.M., et al. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 2012; 14: 130–8. DOI: https://doi.org/10.1111/j.1463–1326.2011.01496.x

9. Gregorio F., Ambrosi F., Cristallini S., Pedetti M., et al. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes Res Clin Pract. 1992; 18: 197–206.

10. Smirnova O.M., Kononenko I.V. Diabeton MB in the treatment of type 2 diabetes mellitus and prevention of its late complications. Farmateka [Pharmateca]. 2011; 16 (229): 30–6. (in Russian)

11. Hinke S.A. Epac2: a molecular target for sulfonylurea-induced insulin release. Sci Signal. 2009; 2 (85): pe54. DOI: https://doi.org/10.1126/scisignal.285pe54

12. Avogaro A. Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes Metab. 2012; 14 (suppl 1): 14–9. DOI: https://doi.org/10.1111/j.1463–1326.2011.01508.x

13. Del Guerra S., Grupillo M., Masini M., et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev. 2007; 23: 234–8. DOI: https://doi.org/10.1002/dmrr.680

14. O’Brien R.C., Luo M., Balazs N., Mercuri J. In-vitro and in-vivo antioxidant properties of gliclazide. J Diabetetes Complications. 2000; 14: 201–6. DOI: https://doi.org/10.1016/S1056–8727(00)00084–2

15. Fava D., Cassone-Faldetta M., et al. Gliclazide improves antioxidant status and nitric oxidemediated vasodilatation in type 2 diabetes. Diabet Med. 2002; 19: 752–57. DOI: https://doi.org/10.1046/j.1464–5491.2002.00762.x

16. Kimura T., Takagi H., Suzuma K., et al. Comparisons between the beneficial effects of different sulphonylurea on ischemia-induced retinal neovascularization. Free Radic Biol Med. 2007; 43: 454–61. DOI: https://doi.org/10.1016/j.freeradbiomed.2007.04.030

17. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism. 2003; 52 (8): 29–34. DOI: https://doi.org/10.1016/S0026–0495(03)00215–4

18. Nokhodchi A., Raja S., Patel P., Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts. 2012; 2(4): 175–87. DOI: https://doi.org/10.5681/bi.2012.027

19. Moreton R.C., Collett J.H. Modified-release peroral dosage forms. In: Aulton M.E. (ed.). Pharmaceutics: the Science of Dosage form Design. 3rded. London: Churchill Livingstone, 2007: 483–99.

20. Francillard M., Frey N., Paraire M., et al. Pharmacokinetics of Diamicron modified release (MR) in 1007 type 2 diabetic patients. J Nutr Health Aging. 2001; 5: 14.

21. Delrat P., Paraire M., Jochemsen R. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos. 2002; 23 (4): 151–7. DOI: https://doi.org/10.1002/bdd.303

22. Sarkar A., Tiwari A., Parminder S., Bhasin P.S., Mitra M. Pharmacological and pharmaceutical profile of gliclazide: a review. J Appl Pharm Sci. 2011; 1 (9): 11–9. URL: https://www.japsonline.com/admin/php/uploads/253_pdf.pdf

23. Guillausseau P.J., Greb W. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes Metab. 2001; 27 (2 Pt 1): 133–7.

24. Crepaldi G., Fioretto P. Gliclazide modified release: its place in the therapeutic armamentarium. Metabolism. 2000; 49 (10 suppl 2): 21–5. DOI: https://doi.org/10.1053/meta.2000.17826

25. Ashcroft F.M., Gribble F.M. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complications. 2000; 14 (4): 192–6. DOI: https://doi.org/10.1016/s1056–8727(00)00081–7

26. Engler R.L., Yellon D.M. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation. 1996; 94: 2297–301. DOI: https://doi.org/10.1161/01.cir.94.9.2297.

27. Standards of specialized diabetes care. Dedov I.I., Shestakova M.V., Mayorov A. Yu. (eds). 9th ed., rev. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (S 1). DOI: https://doi.org/10.14341/DM221S 1 (in Russian)

28. Schopman J.E., et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014; 30:11–22.

29. ACCORD Study Group; Buse J.B., et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99 (12A): 21i-33i. DOI: https://doi.org/10.1016/j.amjcard. 2007.03.003

30. ADVANCE Collaborative Group; Patel A., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358 (24): 2560–72. DOI: https://doi.org/10.1056/NEJMoa0802987

31. VADT Investigators; Duckworth W., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360 (2): 129–39. DOI: https://doi.org/10.1056/NEJMoa0808431

32. Gaede P., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580–91.

33. Zoungas S. ADVANCE in context: the benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release.

Diabetes Obes Metab. 2020; 22 (suppl 2): 5–11. DOI: https://doi.org/10.1111/dom. 13968

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)